Invokana reduces composite endpoint by 30% in Type II diabetics with CKD

After years of failures in the CKD space, two agents have now shown efficacy in the indication. The latest is Invokana canagliflozin from Janssen, which said Sunday that Invokana is the only drug in nearly 20 years and the first diabetes medicine to reduce the risk of renal failure in patients with chronic kidney disease and Type II diabetes.

The other compound, roxadustat from FibroGen Inc. (NASDAQ:FGEN) and AstraZeneca plc (LSE:AZN; NYSE:AZN), is being developed to treat anemia in patients with CKD...